Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 25359

Original article / research
Year : 2018 | Month : August | Volume : 12 | Issue : 8 | Page : DC18 - DC20

Vaccine Therapy in Chronic Hepatitis B Carriers: A Randomised Double-Blind Controlled Trial

Behnaz khodabakhshi, gholamreza roshandel, abdollah abbasi, aida hashemifard, sima besharat, Fatemeh ghasemi kebria, abdolvahab moradi

1. Faculty, Infectious Disease Department, Golestan Research Center of Gastroenterology and Hepatology, Infectious Disease Research Center, Golestan University of Medical Sciences Gorgan, Golestan, Iran. 2. Faculty, MPH, PhD of Epidemiology, Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences Gorgan, Golestan, Iran. 3. Faculty, Infectious Disease Department, Infectious Disease Research Center, Golestan University of Medical Sciences Gorgan, Golestan, Iran. 4. Faculty, Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences Gorgan, Golestan, Iran. 5. Faculty, PhD of Biomedicine, Golestan Research Center of Gastroenterology and Hepatology, Infectious Disease Research Center, Golestan University of Medical Sciences Gorgan, Golestan, Iran. 6. Postgraduate, Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences Gorgan, Golestan, Iran. 7. PhD Stu

Correspondence Address :
Dr. Abdolvahab Moradi,
PhD Student, Department of Virology, Golestan Research Center of Gastroenterology and Hepatology, Third Floor, Research Centers’
Complex, Sayyad-e-Shirazi hospital, Sayyad-e-Shirazi Boulevard, Gorgan City, Golestan Province, Iran, Gorgan, Golestan, Iran.
E-mail: abmoradi @yahoo.com

Abstract

Introduction: Chronic carriers of Hepatitis B Virus (HBV) are persistent sources of the virus and may transmit HBV to healthy individuals.

Aim: This study was conducted to assess therapeutic effects of HBV vaccine on Chronic HBV Carriers (CHC).

Methods and Materials: This clinical trial was conducted on CHCs aged 20-65 years, randomly allocated into four groups. Group 1 (control) did not receive vaccine. Group 2, 3 and 4 (vaccine groups) received different doses of HBV vaccine. HBV viral load (IU/mL) was assessed at baseline and two months after the last dose of HBV vaccine. Reduction or elimination of HBV viral load was considered as positive response. Absolute Response Rates (ARR) was calculated for each group. Subgroup analysis was done on subjects with baseline viral load of <100,000 and negative HBeAb. Relative Response Rates (RRR) was defined as ARR in vaccine group divided by that of control. RRRs were calculated for total participants (overall RRR) and the above-mentioned subgroup of subjects (subgroup RRR).

Results: In total, 97 CHCs were recruited. No adverse reaction was reported. There was no significant difference in ARRs between study groups (p-value=0.09). An overall RRR of 0.78 and a subgroup RRR of 1.18 has been reported. A 50% increase was found in the RRR in subgroups of subjects with baseline viral load of <100,000 and negative HBeAb compared to the overall RRR.

Conclusion: It may be worth future studies to assess the therapeutic effects of HBV vaccine.

Keywords

Chronic carrier state, Hepadnaviridae, Treatment, Vaccination, Viral load

How to cite this article :

Behnaz khodabakhshi, gholamreza roshandel, abdollah abbasi, aida hashemifard, sima besharat, Fatemeh ghasemi kebria, et al.. VACCINE THERAPY IN CHRONIC HEPATITIS B CARRIERS: A RANDOMISED DOUBLE-BLIND CONTROLLED TRIAL. Journal of Clinical and Diagnostic Research [serial online] 2018 August [cited: 2018 Jul 16 ]; 12:DC18-DC20. Available from
http://jcdr.net/back_issues.asp?issn=0973-709x&year=2018&month=August&volume=12&issue=8&page=DC18-DC20&id=11899

DOI and Others

DOI: 10.7860/JCDR/2018/33890.11899

Date of Submission: Oct 09, 2017
Date of Peer Review: Feb 07, 2018
Date of Acceptance: May 26, 2018
Date of Publishing: Aug 01, 2018

FINANCIAL OR OTHER COMPETING INTERESTS: None.

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2016: 132.37
  • SCOPUS
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • EBSCOhost
  • Embase & EMbiology
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com